title: Intravenous administration of tetramethylpyrazine reduces intestinal ischemia-reperfusion injury in rats.
abstract: Intestinal ischemia-reperfusion injury (IIRI) is a life-threatening condition requiring prompt medical intervention. Tetramethylpyrazine (TMP) is a biologically active alkaloid isolated from Ligusticum wallichii. Previously, it was shown that TMP causes vasodilatation and inhibition of platelet aggregation as well as exhibits significant antioxidant effects. Therefore, the aim of the present study was to evaluate possible therapeutic effects of TMP in the prevention of IIRI. Wistar rats (n = 80) were randomly divided into eight experimental groups and subjected to a 1 h occlusion of cranial mesenteric artery followed by 0, 1, 12, and 24 h period of reperfusion. Thirty minutes before the IIRI animals received either TMP (30 mg/kg, i.v.) or identical volume of saline. In addition, a control group of 10 animals was not exposed to IIRI. Intestine morphology was evaluated by using histopathological injury index examination (HII), goblet and Paneth cells quantification as well as by applying immunofluorescent methods such as InSitu TUNEL and caspase-3 positivity assessment. Here we showed that preconditioning with TMP prior IIRI decreases the grade of injury. Significant reduction of HII was detected in TMP pretreated groups after 0, 1, and 12 h of reperfusion where injury reduction up to 75% was found. Lower histopathological damage in preconditioned groups was accompanied with increased number of secretory epithelial cells and decreased number of apoptotic cells. These results demonstrate the protective effect of TMP on the small intestine mucosa, suggesting administration of TMP as a molecule for pharmacological intervention against IIRI.
authors.affiliation: Department of Histology and Embryology, Faculty of Medicine, Pavol Jozef Šafárik University, Slovakia. stefan.toth@me.com
authors.forename: Štefan
authors.initials: Š
authors.lastname: Tóth
authors.forename: Tímea
authors.initials: T
authors.lastname: Pekárová
authors.forename: Ján
authors.initials: J
authors.lastname: Varga
authors.forename: Štefan
authors.initials: Š
authors.lastname: Tóth
authors.forename: Vladimíra
authors.initials: V
authors.lastname: Tomečková
authors.forename: Peter
authors.initials: P
authors.lastname: Gál
authors.forename: Jarmila
authors.initials: J
authors.lastname: Veselá
authors.forename: Juraj
authors.initials: J
authors.lastname: Guzy
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D004195:Disease Models, Animal; D020397:Goblet Cells / Q000187:drug effects / Q000473:pathology; D007413:Intestinal Mucosa / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D007583:Jejunum / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008638:Mesenteric Arteries; D008641:Mesenteric Vascular Occlusion / Q000473:pathology*; D019879:Paneth Cells / Q000187:drug effects / Q000473:pathology; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000473:pathology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D011719:Pyrazines; D014665:Vasodilator Agents; C017953:tetramethylpyrazine